Welcome to OncLive On Air®! I’m your host at the moment, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which offers oncology professionals with the assets and data they should present one of the best affected person care. In each digital and print codecs, OncLive® covers each angle of oncology observe, from new know-how to therapy advances to essential regulatory selections.
In at the moment’s episode, we had the pleasure of talking with presenters from the 2023 SGO Annual Assembly, who shared their insights on the therapy of sufferers with gynecologic cancers.
Ursula A. Matulonis, MD, mentioned last total survival (OS) information from the section 3 NOVA trial (NCT01847274) of niraparib (Zejula) in sufferers with recurrent ovarian most cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Household Chair at Dana-Farber Most cancers Institute and a professor of medication at Harvard Medical College, each in Boston, Massachusetts.
Robert L. Coleman, MD, FACOG, FACS, mentioned findings from an analysis of the antitumor results of therapy sequencing with mirvetuximab soravtansine-gynx (Elahere) within the section 3 SORAYA trial (NCT04296890) in sufferers with folate receptor alpha–excessive, platinum-resistant ovarian most cancers. Dr Coleman is the chief scientific officer of US Oncology Analysis in Houston, Texas.
Cara Mathews, MD, mentioned 7-year OS information from the section 3 SOLO-1 trial (NCT01844986) in sufferers with newly identified, BRCA-mutated, superior ovarian most cancers who acquired upkeep olaparib (Lynparza). Dr Mathews is an affiliate professor of obstetrics and gynecology at Brown College and a gynecologic oncologist at Ladies & Infants Hospital, each in Windfall, Rhode Island.
Ramez N. Eskander, MD, mentioned findings from the section 3 NRG GY018 trial (NCT03914612) of pembrolizumab (Keytruda) plus paclitaxel and carboplatin in sufferers with stage III, IVA, or IVB endometrial most cancers. Dr Eskander is an assistant professor of obstetrics, gynecology, and reproductive sciences on the College of California San Diego Moores Most cancers Middle.
Lastly, Mansoor Raza Mirza, MD, mentioned findings from the interim evaluation of the section 3 RUBY trial (NCT03981796) of dostarlimab-gxly (Jemperli) plus chemotherapy in sufferers with main superior or recurrent endometrial most cancers. Dr Mirza is chief oncologist within the Division of Oncology at Rigshospitalet, Copenhagen College Hospital in Denmark.
___
That’s all we’ve got for at the moment! Thanks for listening to this episode of OncLive On Air®. Test again on Mondays and Thursdays for unique interviews with main consultants within the oncology discipline.
For extra updates in oncology, make sure to go to www.OncLive.com and join our e-newsletters.
OncLive® can be on social media. On Twitter, comply with us at @OncLive and @OncLiveSOSS. On Fb, like us at OncLive and OncLive State of the Science Summit and comply with our OncLive web page on LinkedIn.
When you appreciated at the moment’s episode of OncLive On Air®, please think about subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and plenty of of your different favourite podcast platforms,* so that you get a notification each time a brand new episode is posted. While you’re there, please take a second to fee us!
Thanks once more for listening to OncLive On Air®.
*OncLive On Air® is accessible on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Pay attention Notes, Participant FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
